Clinical trial · Interventional
Evaluation of the Safety and Efficacy of Single-Port Robot-Assisted Endoscopic Breast-Conserving Surgery and Nipple-sparing Matectomy With Reconstruction in Early-Stage Breast Cancer Patients
Evaluation of the Safety and Efficacy of Single-Port Robot-Assisted Endoscopic Breast-Conserving Surgery and Nipple-Sparing Mastectomy With Reconstruction in Early-Stage Breast Cancer Patients: A Single-Center, Single-Arm, Prospective Interventional Clinical Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is testing a new, less invasive way to perform breast cancer surgery using a single-port robotic system (a robot-assisted surgical tool made in China, called the Shurui SR-ENS-600). The robot works through one small hidden incision (about 3-4 cm) in the armpit or under the breast fold, instead of multiple cuts or a large open wound. We want to find out whether this robot-assisted surgery is safe and effective for women with early-stage breast cancer who need either: Breast-conserving surgery (lumpectomy), or Total removal of breast tissue with immediate reconstruction using a breast implant. You may be able to join if you: Are a woman aged 18-70 years; Have been diagnosed with early-stage breast cancer (by biopsy); Are suitable for either breast-conserving surgery or mastectomy with immediate implant reconstruction; Are in good general health (able to tolerate surgery and anesthesia); Are willing to receive the robotic surgery and complete the follow-up visits. If you join, you will: Receive the robotic surgery as your main treatment; Stay in the hospital for a short period after surgery (about 1-7 days); Come back for follow-up visits at 1, 3, 6, 12, and 24 months after surgery; Be asked to complete a few simple questionnaires about your recovery, satisfaction with breast appearance, and quality of life.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| single-port robot-assisted surgery | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- single-port
- description
- Patients in this arm will have single-port robot-assisted breast surgery
- interventionNames
- Procedure: single-port robot-assisted surgery
Primary outcomes (1)
- measure
- Surgical success rate
- timeFrame
- Perioperative
- description
- Defined as robotic surgery completed without conversion to conventional open surgery or conventional endoscopic/laparoscopic surgery, with R0 resection achieved.
Secondary outcomes (4)
- measure
- Total operative time
- timeFrame
- Perioperative
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Female patients aged 18 to 80 years; 2. Histopathologically confirmed invasive breast cancer or ductal carcinoma in situ (DCIS); 3. Clinical stage I-II for breast-conserving surgery, or clinical stage I-III for subcutaneous mastectomy with immediate prosthetic reconstruction; 4. Planned to undergo breast-conserving surgery or subcutaneous mastectomy with immediate prosthetic reconstruction; 5. For breast-conserving surgery: maximum tumor diameter ≤ 3 cm, with a favorable tumor-to-breast volume ratio for breast conservation; 6. For subcutaneous mastectomy with immediate prosthetic reconstruction: willingness and appropriate indication for prosthetic reconstruction, with moderate breast volume; 7. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1; 8. American Society of Anesthesiologists (ASA) physical status classification I-III; 9. Adequate vital organ function meeting the following criteria: Hematology: absolute neutrophil count ≥ 1.5 × 10⁹/L, platelet count ≥ 90 × 10⁹/L, hemoglobin ≥ 90 g/L; Liver function: total bilirubin ≤ 1.5 × upper limit of normal (ULN), ALT and AST ≤ 2.5 × ULN; Renal function: creatinine ≤ 1.5 × ULN; Coagulation function: INR ≤ 1.5, APTT ≤ 1.5 × ULN; 10. Voluntary participation with written informed consent signed. Exclusion Criteria: 1. Prior history of breast surgery (excluding biopsy procedures); 2. Prior history of chest wall radiotherapy; 3. Pregnant or lactating women; 4. Concurrent malignancy (excluding adequately treated basal cell carcinoma of the skin or carcinoma in situ of the cervix); 5. Severe cardiopulmonary dysfunction precluding tolerance to general anesthesia; 6. Severe hepatic or renal insufficiency; 7. Coagulation disorders or ongoing anticoagulant therapy that cannot be discontinued; 8. Active infection, particularly in the breast region; 9. Allergy or intolerance to silicone implant materials (for patients undergoing prosthetic reconstruction); 10. Severe breast ptosis or excessively large breast volume (for patients undergoing prosthetic reconstruction); 11. Presence of any contraindication to surgery, or any condition that the investigator deems unsuitable for study participation.
References
Publications (0)
Data not yet available